Marksans Pharma, in an exchange filing, said its wholly-owned subsidiary Marksans Pharma Inc’s Abbreviated New Drug Application received the final approval from the US Food and Drug Administration (USFDA) for the over-the-counter Loperamide Hydrochloride Tablets USP, 2 mg.
